Leaked Data Boost J&J and Legend’s CAR-T Carvykti But Manufacturing Issues Remain

Risk Of Progression Or Death Cut By 74%

An accidental peek at data suggests Carvykti can outperform Bristol Myers Squibb’s rival CAR-T therapy Abecma, if it can prove a survival benefit and overcome manufacturing limitations that are hampering both products.

J&J building
The leaked data appears to confirm that Carvykti has the upperhand on BMS's rival • Source: Shutterstock

Johnson & Johnson and Legend Biotech have received an unexpectedly early boost for their CAR-T drug, Carvykti, in the shape of a leaked abstract for theh CARTITUDE-4 study showing it can cut risk of tumor progression or death by an impressive 74% compared with standard therapy.

That backs up belief that it will outperform its fellow BCMA targeting rival, Bristol Myers Squibb’s Abecma. Both products...

More from Business

More from Scrip